Quest Diagnostics Aktie 566162 / US74834L1008
168.07
USD
-3.47
USD
-2.02 %
11.07.2025
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Quest Diagnostics Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | Quest Diagnostics Inc. | 1.99 | 3.00 | USD |
| 2023 | Quest Diagnostics Inc. | 2.06 | 2.84 | USD |
| 2022 | Quest Diagnostics Inc. | 1.69 | 2.64 | USD |
| 2021 | Quest Diagnostics Inc. | 1.43 | 2.48 | USD |
| 2020 | Quest Diagnostics Inc. | 1.88 | 2.24 | USD |
| 2019 | Quest Diagnostics Inc. | 1.99 | 2.12 | USD |
| 2018 | Quest Diagnostics Inc. | 2.44 | 2.03 | USD |
| 2017 | Quest Diagnostics Inc. | 1.83 | 1.80 | USD |
| 2016 | Quest Diagnostics Inc. | 1.80 | 1.65 | USD |
| 2015 | Quest Diagnostics Inc. | 2.14 | 1.52 | USD |
Gewinn je Aktie- Quest Diagnostics
| 7.7 24 | 7.5 23 | 8.0 22 | 15.6 21 | 10.5 20 | 6.3 19 | 5.3 18 |
Umsatz je Aktie- Quest Diagnostics
| 87.4 24 | 81.9 23 | 83.8 22 | 84.3 21 | 69.4 20 | 56.8 19 | 54.2 18 |
KGV- Quest Diagnostics
| 19.7 24 | 18.3 23 | 19.6 22 | 11.1 21 | 11.3 20 | 17.0 19 | 15.8 18 |
Quest Diagnostics Inc.: Die Aktie (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (berichtet) | 7.69 | 7.49 | 7.97 | 15.55 | 10.47 | 6.28 | 5.29 |
| Gewinn je Aktie (unverwässert) | 7.80 | 7.59 | 8.12 | 15.90 | 10.68 | 6.38 | 5.39 |
| Gewinn je Aktie (verwässert) | 7.66 | 7.52 | 7.98 | 15.53 | 10.52 | 6.29 | 5.27 |
| Dividende je Aktie | 3.00 | 2.84 | 2.64 | 2.48 | 2.24 | 2.12 | 2.03 |
| Veränderung Dividende je Aktie in % | 5.63 | 7.58 | 6.45 | 10.71 | 5.66 | 4.43 | 12.78 |
| Gesamtdividendenausschüttung in Mio. | 331.00 | 314.00 | 305.00 | 309.00 | 297.00 | 286.00 | 266.00 |
Quest Diagnostics Inc.: Unternehmenskennzahlen (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 87.36 | 81.88 | 83.75 | 84.28 | 69.39 | 56.81 | 54.18 |
| KGV (Jahresendkurs, Gewinn unverwässert) | 19.69 | 18.33 | 19.60 | 11.14 | 11.33 | 16.99 | 15.79 |
| KGV (Jahresendkurs, Gewinn verwässert) | 19.69 | 18.33 | 19.60 | 11.14 | 11.33 | 16.99 | 15.79 |
| Dividendenrendite Jahresende in % | 1.99 | 2.06 | 1.69 | 1.43 | 1.88 | 1.99 | 2.44 |
| Eigenkapitalquote in % | 42.69 | 45.77 | 46.79 | 48.21 | 49.13 | 44.87 | 48.57 |
| Fremdkapitalquote in % | 57.31 | 54.23 | 53.21 | 51.79 | 50.87 | 55.13 | 51.43 |
Quest Diagnostics Inc.: GuV (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 9’872.00 | 9’252.00 | 9’883.00 | 10’788.00 | 9’437.00 | 7’726.00 | 7’531.00 |
| Umsatzveränderung in % | 6.70 | -6.38 | -8.39 | 14.32 | 22.15 | 2.59 | -2.31 |
| Bruttoergebnis vom Umsatz | 3’146.00 | 2’961.00 | 3’347.00 | 4’140.00 | 3’614.00 | 2’628.00 | 2’583.00 |
| Bruttoergebnisveränderung in % | 6.25 | -11.53 | -19.15 | 14.55 | 37.52 | 1.74 | -12.91 |
| Operatives Ergebnis | 1’415.00 | 1’351.00 | 1’622.00 | 2’444.00 | 2’105.00 | 1’220.00 | 1’224.00 |
| Veränderung Operatives Ergebnis in % | 4.74 | -16.71 | -33.63 | 16.10 | 72.54 | -0.33 | -4.60 |
| Ergebnis vor Steuern | 1’175.00 | 1’130.00 | 1’235.00 | 2’599.00 | 1’884.00 | 1’076.00 | 926.00 |
| Veränderung Ergebnis vor Steuern in % | 3.98 | -8.50 | -52.48 | 37.95 | 75.09 | 16.20 | -10.10 |
| Ergebnis nach Steuer | 866.00 | 850.00 | 942.00 | 1’988.00 | 1’425.00 | 835.00 | 733.00 |
| Veränderung Ergebnis nach Steuer in % | 1.88 | -9.77 | -52.62 | 39.51 | 70.66 | 13.92 | -4.68 |
Quest Diagnostics Inc.: Bilanz (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Fremdkapital | 9’257 | 7’604 | 6’830 | 7’049 | 7’135 | 7’080 | 5’659 |
| Langzeit Gesamtverbindlichk. je Aktie | 63.86 | 52.15 | 47.56 | 44.50 | 40.29 | 38.27 | 30.92 |
| Eigenkapital | 6’896 | 6’418 | 6’007 | 6’562 | 6’891 | 5’763 | 5’344 |
| Veränderung Eigenkapital in % | 7.47 | 7.03 | -8.55 | -4.66 | 19.82 | 8.15 | 5.99 |
| Bilanzsumme | 16’153 | 14’022 | 12’837 | 13’611 | 14’026 | 12’843 | 11’003 |
| Veränderung Bilanzsumme in % | 15.20 | 9.23 | -5.69 | -2.96 | 9.21 | 16.72 | 4.76 |
Quest Diagnostics Inc.: Sonstige Angaben (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 7.80 | 7.59 | 8.12 | 15.90 | 10.68 | 6.38 | 5.39 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 2.80 | -6.54 | -48.94 | 48.93 | 67.37 | 18.39 | -3.98 |
| Gewinn je Aktie (verwässert) | 7.66 | 7.52 | 7.98 | 15.53 | 10.52 | 6.29 | 5.27 |
| Veränderung Gewinn je Aktie (verwässert) in % | 1.88 | -5.77 | -48.60 | 47.61 | 67.37 | 19.22 | -4.00 |
| Anzahl Mitarbeiter | 56’000 | 48’000 | 49’000 | 49’000 | 49’000 | 47’000 | 46’000 |
| Veränderung Anzahl Mitarbeiter in % | 16.67 | -2.04 | 0.00 | 0.00 | 4.26 | 2.17 | 2.22 |
Quest Diagnostics Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Quest Diagnostics Inc. | Quartalszahlen | 22.07.2025 |
| Quest Diagnostics Inc. | Quartalszahlen | 28.10.2025 |
| Quest Diagnostics Inc. | Quartalszahlen | 29.01.2026 |
| Quest Diagnostics Inc. | Quartalszahlen | 28.04.2026 |
| Quest Diagnostics Inc. | Quartalszahlen | 28.07.2026 |
Quest Diagnostics Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Hauptversammlung | Annual General Meeting | 15.05.2025 |
| Quartalszahlen | Q1 2025 Earnings Release | 22.04.2025 |
| Quartalszahlen | Q4 2024 Earnings Release | 30.01.2025 |
| Quartalszahlen | Q3 2024 Earnings Release | 22.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 23.07.2024 |
| Hauptversammlung | Annual General Meeting | 16.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 23.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 01.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 24.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 26.07.2023 |
| Hauptversammlung | Annual General Meeting | 17.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 02.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 20.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 21.07.2022 |
| Hauptversammlung | Annual General Meeting | 18.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 21.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 03.02.2022 |
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 46’000 | 47’000 | 49’000 | 49’000 | 49’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.16 | 0.16 | 0.19 | 0.22 | 0.20 |
Bilanz (in Mio. USD) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1’390 | 2’490 | 3’058 | 2’741 | 1’898 |
| Summe Anlagevermögen | 9’613 | 10’353 | 10’968 | 10’870 | 10’939 |
| Summe Aktiva | 11’003 | 12’843 | 14’026 | 13’611 | 12’837 |
Bilanz (in Mio. USD) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 5’659 | 7’080 | 7’135 | 7’049 | 6’830 |
| Summe Eigenkapital | 5’344 | 5’763 | 6’891 | 6’562 | 6’007 |
| Summe Passiva | 11’003 | 12’843 | 14’026 | 13’611 | 12’837 |
Adresse
| 500 Plaza Drive, 07940 Secaucus | |
| Telefon | +1 (973) 520-2700 |
| URL | http://www.questdiagnostics.com |
Management
|
Adrienne L. Brott
Chief Quality & Regulatory Affairs Officer, SVP |
|
Alyssa Waxenberg
Senior Director-Patient Digital Products |
|
Catherine T. Doherty
Executive Vice President-Regional Businesses |
|
Cecilia K. McKenney
Chief Human Resources Officer & Senior VP |
|
Darren Wheeler
Vice President-Pathology & Medical Services |
|
Denise M. Morrison
Independent Director |
|
Dermot Victor Shorten
Senior Vice President-Ventures, Strategy, M&A |
|
Doug Lang
Director-Technical Products |
|
Garry Clark
Chief Marketing & Communications Officer, SVP |
|
Gary M. Pfeiffer
Independent Director |
|
James E. Davis
Chairman, President & Chief Executive Officer |
|
Karthik Kuppusamy
Senior Vice President-Clinical Solutions |
|
Kristin Wallace
Chief Compliance Officer & Senior Vice President |
|
Luis A. Diaz
Independent Director |
|
Mark E. Delaney
Chief Commercial Officer & Senior Vice President |
|
Mark Gardner
Senior Vice President-Oncology & Genomics |
|
Michael E. Prevoznik
Senior Vice President & General Counsel |
|
Michael Joseph Deppe
Chief Accounting Officer, SVP & Controller |
|
Murali Balakumar
Chief Information & Digital Officer, Senior VP |
|
Patrick Plewman
Senior Vice President-Diagnostic Services |
|
Robert B. Carter
Independent Director |
|
Sam A. Samad
Chief Financial Officer & Executive Vice President |
|
Sean D. Mersten
Secretary & Vice President |
|
Shawn Bevec
Vice President-Investor Relations |
|
Timothy L. Main
Independent Director |
|
Timothy M. Ring
Lead Independent Director |
|
Tracey C. Doi
Independent Director |
|
Tracy L. Cinco-Abela
Treasurer & Vice President |
|
Vicky B. Gregg
Independent Director |
|
Wright L. Lassiter
Independent Director |
|
Yuri A. Fesko
Chief Medical Officer & Senior Vice President |